9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
The DOI matches its Crossref record; 90 of the 94 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc21-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc21-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the latest American Diabetes Association (ADA) [62], Italian Society of Diabetology (SID) [63] and KDIGO guidelines [64] differentiate the pharmacological approach to T2DM not just based on the target glycaemic values but also taking into account the indicators of high-risk or established atherosclerotic cardiovascular disease, CKD and heart failure.”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [62]
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 1×
“temshasbeensupported in the literature in adolescents and adults with type 1 diabetes (16,17), and recent evidence suggests that a closed-loop system is superior to sensor-augmented pump therapy for glycemic control and reduction of hypoglycemia over 3 months of comparison in children and adults with type 1 diabetes (…”
BackgroundHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Research works printed but not linked: 3
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
- Chiang, 2014, Type 1 diabetes through the life span: a position statement of the American Diabetes Association
- Lipska, 2018, Association of initiation of basal insulin analogs vs neutral protamine hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes, 53
Cited by
Items 901–975 of 975
Zheng, J., Lu, J., Qi, J., Yang, Q., Zhao, H., Liu, H., Ye, Y., Xu, M., Xu, Y., Wang, T., et al. (2023) · medRxiv · doi:10.1101/2023.10.10.23296790
“…evidence, the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) guidelines recommended SGLT2 inhibitors as first-line therapy for patients with or with indicators of high risk of ASCVD, heart failure, or chronic kidney disease (CKD) since 2020 5,6,7 .”
BackgroundAllam, M. M., Younan, M., Abdelhamid, M., Khan, M. A., Elshafee, M., & Nada, A. M. (2023) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000295
“The regular care was implemented according to ADA standards of care [11].”
MethodConcise review on anti-diabetic agents: Traditional to modern
Dave, N., Shah, J. P., & Khodakiya, A. (2023) · Current Trends in Pharmacy and Pharmaceutical Chemistry · doi:10.18231/j.ctppc.2023.026 · Cited by 1
Mishra, A., Dongre, S. A., Kulkarni, G. S., Deshmane, R. B., Thappa, D. M., Ghade, N. S., Lona, J., Kokatam, S., Deo, A., Sonar, S., et al. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02263-5
Müller‐Wieland, D., & Marx, N. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-62932-1_12
Non‐insulin Parenteral Therapies
Vilsbøll, T., Christensen, M., Andersen, A., & Knop, F. K. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch36
Achieving Effective Weight Loss for Type 2 Diabetes Mellitus Control: From Evidence to Practice
Chan, S. L. (2023) · The Singapore Family Physician · doi:10.33591/sfp.49.3.u2
Nonalcoholic fatty liver disease: What comes before and what are the consequences?
Bril, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-88426-6.00017-8
Nguyen, C., Crowe, C. L., Kuti, E. L., Donato, B. M. K., DJARAHER, R. L., SEMAN, L. J., Graeter, N., Power, T. P., Mehra, R., & Willey, V. J. (2014) · Journal of health economics and outcomes research · doi:10.36469/jheor.2024.92368
Coulson, H. C., Brown, M., Burke, K., Griffith, E., Shadiack, V., Garner, H. R., & Foushee, J. A. (2024) · Journal of Osteopathic Medicine · doi:10.1515/jom-2022-0251
SGLT2 and GLP - 1 Inhibitors: Enlightening their Role beyond their Glucose Lowering Properties
Mehra, G. (2024) · International Journal of Science and Research (IJSR) · doi:10.21275/sr24408120904
Alidrisi, H. A., Odhaib, S. A., Nwayyir, H. A., & Almomin, A. (2024) · Clinical Diabetology · doi:10.5603/cd.99656 · Cited by 1
Thực trạng kê đơn thuốc cho bệnh nhân đái tháo đường tuýp 2 tại Bệnh viện Thống Nhất năm 2023
Bui, T., Lưu, G. L., Bảy, V. V., & Thủy, N. T. T. T. N. T. T. (2024) · TẠP CHÍ KHOA HỌC TRƯỜNG ĐẠI HỌC QUỐC TẾ HỒNG BÀNG · doi:10.59294/hiujs.29.2024.614 · Cited by 1
A Comprehensive Review of Emerging Therapies for Type 2 Diabetes and Their Cardiovascular Effects
G, A. J. A., Chitneni, E., Vidals, C. J. M., Modumudi, S., Hammad, S., Verma, A., Rajesh, R. Y., Khaliq, A., Adeyemi, O. T., Abid, F., et al. (2024) · Cureus · doi:10.7759/cureus.65707 · Cited by 4
How Did the GLP-1RA and SGLT-2i Affect Serum Uric Acid in Diabetic Patients?
李, 白. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1482223
Multicomponent Insulin Regimens
Steenkamp, D. (2021) · American Diabetes Association eBooks · doi:10.2337/9781580407694.ch06
Current Approach of Diabetes Mellitus in Obese Patients
Karaburgu, S. (2023) · doi:10.69860/nobel.9786053359111.8
NBF2, an Algal Fiber-Rich Formula, Reverses Diabetic Dyslipidemia and Hyperglycemia In Vivo
Ngatu, N. R., Hossain, A., Maruo, N., Akumwami, S., Rahman, A., Eitoku, M., Kanda, K., Nishiyama, A., Suganuma, N., & Hirao, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910828
Sayed, A. H., Ahmed, A. S., Hozayn, M., Mohawed, O. A. M., Ahmed, H. H., & Abohashem, R. S. (2024) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2966
Cohort profile: the Nanjing Diabetes Cohort database – a population-based surveillance cohort
Feng, W., Yin, Y., Gu, C., Mu, Y., Zhang, D., Tao, Z., Yin, W., Zhang, X., Yu, Y., Hu, J., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-087498
Lemoine, E., Dusenne, M., & Schuers, M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0314287
(2022) · American Diabetes Association eBooks · doi:10.2337/9781580407700.ch03
A comprehensive approach to diabetic foot ulcers treatment in patients with anisomelia
Ivanova, A., Melekhovets, O. K., & Melekhovets, Y. V. (2025) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.21.2.2025.1511
Lazrak, S., Ouaouda, O., Bektachi, J., Iraqi, M. A., Khabbaz, C. E., & Cherrah, Y. (2025) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1528
Tan, J., Lim, G. H., Tan, H. Y., Sng, G. G. R., Thumboo, J., & Mong, B. Y. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5236698
Mohan, V., Sethi, B. K., Jain, S. M., Sahay, R. K., Balamurugan, R., Murthy, S., Singh, K. P., MENON, S. K., Gadekar, A. V., Salvi, V., et al. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01736-5 · Cited by 1
“Lifestyle modifications and oral glucose-lowering drugs are often recommended as first-line interventions in treating T2D [5].”
Once Weekly Insulin: The Battle of 52 versus 365
Thomas, J. J., & Mathews, N. (2025) · Open Journal of Internal Medicine · doi:10.4236/ojim.2025.152010
Evaluating Genetic Obesity Interventions: A Survival Analysis Approach
Zaidan, S. R. (2025) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v8i2.1926
“A biguanide derivative is a widely prescribed oral medication primarily used for the management of type 2 diabetes due to its ability to improve insulin sensitivity and reduce hepatic glucose production [10].”
Ajao, F. O., Adeyeye, I. O., Kalejaiye, N. O., Mukaila, S. O., Agboola, O. S., & Iyedupe, M. O. (2025) · Annals of Clinical Gastroenterology and Hepatology · doi:10.29328/journal.acgh.1001050
PECULIARITIES OF THE FORMATION OF UNILATERAL DIABETIC TROPHIC ULCERS
Ivanova, A., Melekhovets, O. K., Melekhovets, Y. V., & Spivak, Z. (2025) · PROBLEMS OF ENDOCRINE PATHOLOGY · doi:10.21856/j-pep.2025.2.02
Poonawalla, I. B., Abdal, P., Hayes, M., John, I., Diaz, M., Dixon, S. W., & Bowe, A. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.31.7.627 · Cited by 1
A comprehensive review of oral hypoglycaemic drugs and their oral health correlates
Bhardwaj, N., & Mehta, S. (2025) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20252160
Altom, S. A. A., Alhajri, A. H. M., Ali, H. K. M., Ahmed, D. A. M., Rahma, M. A. R., Ahmed, T. A. M., Alatif, M. M. M. A., & AHMED, R. (2025) · Cureus · doi:10.7759/cureus.93456
Lian, D., Liu, J., Wei, Y., Yang, Y., Ren, Y., Bao, S., Liu, L., Liu, S., & Chen, Y. (2025) · Patient · doi:10.1007/s40271-025-00776-0
“However, owing to the progressive nature of the disease and poor adherence to therapy, approximately 50% of patients fail to achieve glycemic targets within a 3-year period, thus requiring combination therapy to achieve adequate glycemic control [4–7].”
Zahniar, Z., Khairunnisa, K., & Wiryanto, W. (2025) · Journal of Pharmaceutical And Sciences · doi:10.36490/journal-jps.com.v8i4.1087
Liu, H., Li, T., Yu, H., Chen, X., Li, J., Tan, H., & Yu, Y. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01590-5 · Cited by 1
“Insulin therapy is essential for all patients with type 1 diabetes and some with type 2 diabetes to normalize blood glucose (BG) levels [2, 3].”
Tamatea, J. A. U., Karu, L. T., Grey, C., Jansen, R. M., Jordan, A., Loring, B., & Reid, P. (2025) · Health Systems & Reform · doi:10.1080/23288604.2025.2592386
“26 Medsafe first approved a GLP-1 agonist for use in NZ in 2007, and a SGLT-2 inhibitor in 2015, 27 enabling them to be purchased privately at high cost to the patient.”
Müller‐Wieland, D., & Marx, N. (2024) · Springer eBooks · doi:10.1007/978-3-662-69938-6_12
Moazzeni, S. S., Hizomi Arani, R., Deravi, N., Hasheminia, M., Khalili, D., Azizi, F., & Hadaegh, F. (2021) · Figshare · doi:10.6084/m9.figshare.14966167
Nazu, N. A., Wikström, K., Lamidi, M.-L., Lindström, J., Tirkkonen, H., Rautiainen, P., & Laatikainen, T. (2022) · Figshare · doi:10.6084/m9.figshare.21532609
Tye, S. C., Jongs, N., Coca, S. G., Sundström, J., Arnott, C., Neal, B. C., Perkovic, V., Mahaffey, K. W., Vart, P., & Heerspink, H. J. L. (2022) · Figshare · doi:10.6084/m9.figshare.21200741
Vencio, S., Vianna, A. G. D., da Silva, M. A. C. F., & Precoma, D. B. (2022) · Figshare · doi:10.6084/m9.figshare.18132637
Guo, L., Wang, J., Li, L., Yuan, L., Chen, S., Wang, H., Li, T., Qi, L., & Yang, H. (2024) · Figshare · doi:10.6084/m9.figshare.26597261
Hao, R. C., Myroniuk, T., McGuckin, T., Manca, D., Campbell-Scherer, D., Lau, D., & Yeung, R. O. (2022) · Figshare · doi:10.6084/m9.figshare.19844664
Fang, H. S. A., Gao, Q., Tan, W. Y., Lee, M. L., Hsu, W., & Tan, N. C. (2022) · Figshare · doi:10.6084/m9.figshare.19069822
Moazzeni, S. S., Hizomi Arani, R., Deravi, N., Hasheminia, M., Khalili, D., Azizi, F., & Hadaegh, F. (2021) · Figshare · doi:10.6084/m9.figshare.14966161
Fang, H. S. A., Gao, Q., Tan, W. Y., Lee, M. L., Hsu, W., & Tan, N. C. (2022) · Figshare · doi:10.6084/m9.figshare.19069819
Hao, R. C., Myroniuk, T., McGuckin, T., Manca, D., Campbell-Scherer, D., Lau, D., & Yeung, R. O. (2022) · Figshare · doi:10.6084/m9.figshare.19844661
Choi, J., Lee, S., Choi, E., Lee, H., Han, M., Ahn, H.-J., Kwon, S., Lee, S.-W., Han, K., Oh, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22609546
Schechter, M., Cohen, C. M., Rozenberg, A., Yanuv, I., Chodick, G., Karasik, A., Kosiborod, M., & Mosenzon, O. (2021) · Figshare · doi:10.6084/m9.figshare.15253888
Moazzeni, S. S., Hizomi Arani, R., Deravi, N., Hasheminia, M., Khalili, D., Azizi, F., & Hadaegh, F. (2021) · Figshare · doi:10.6084/m9.figshare.14966164
Szépkúti, S., Bandur, S., Kovács, G., Ferenci, T., Svébis, M. M., Turbucz, P., & Tabák, Á. G. (2022) · Figshare · doi:10.6084/m9.figshare.21117530
Everyday Practice in Blood Glucose Management During Perioperative Cardiac Surgery
Elarref, M., Hassan, W. M., & Elarif, N. M. (2025) · Springer eBooks · doi:10.1007/978-3-032-09817-7_8
AI Systems Real-Time Focused Screening of Diabetic Retinopathy Using Deep Learning
Nagaraju, P., Sameer, T. S., Shankar, B. N., Naveen, V. S., Joseph, Y. S., & Sandeep, S. S. (2026) · Lecture notes in networks and systems · doi:10.1007/978-3-032-08246-6_7
de Vries, R., Reinders, E. F. H., de Carvalho, D. F., de Meulengraaf, E. M. W. L. C. V., Gorp, P. M. E. V., Poppel, P. W., Kaymak, U., Hilbers, P. A. J., van Riel, N. A. W., & Haak, H. R. (2026) · Diabetes Technology and Obesity Medicine · doi:10.1177/29986702261416447
New therapeutic options for reducing atherosclerotic cardiovascular disease residual risk
Wong, N. D. (2021) · Srce i krvni sudovi · doi:10.5937/siks2104251w
Menopoz ve Diyabet: Kadın Sağlığında Çift Yönlü Bir İlişki
Bilgiç, D., & Sıdan, M. (2026) · İzmir Katip Çelebi Üniversitesi Sağlık Bilimleri Fakültesi Dergisi · doi:10.61399/ikcusbfd.1699367 · Cited by 1
Pan, M., Wang, P., Wang, X., Wang, Z., Zhang, Z., Yang, K., Liu, W., Ma, W., & Liu, X. B. (2026) · Medicine · doi:10.1097/md.0000000000047533 · Cited by 1
“[4] In contrast, TCM treats DM through syndrome differentiation and the use of plant medicine, offering higher safety and a comprehensive therapeutic effect that addresses both symptoms and root causes, demonstrating good development potential.”
Komatsu, M., Kobayashi, H., Tsuboi, S., & Watada, H. (2026) · Diabetology International · doi:10.1007/s13340-026-00877-7
Stephenson, J. J., Witkowski, N. A., Smith, J., Wong, A. C.-Y., Bengtson, L. G. S., & Willey, V. J. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s573007
Campbell, I. W., Brand, K. M. G., Gottwald‐Hostalek, U., & Dettenbach, J. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03592-6
Teklay, G., Tafere, H., & Niriayo, Y. L. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02332-9
“Metformin is effective, safe, inexpensive, and reduces the risk of cardiovascular events and death [4–6].”
InfluentialKusniawati, K., Yuningsih, D., Sari, C., Rokayah, Y., Irawati, P., & Dewi, V. (2026) · Rawal Medical Journal · doi:10.5455/rmj.20251218063427
Bafail, D. A., & Ghazal, H. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1826021 · Cited by 1
前川, 聡., Yagi, N., Komiya, I., Keiko, A. R. A. I., Oishi, M., Fukumoto, Y., SHIRABE, S., YOKOYAMA, H., Yamazaki, K., Sugimoto, H., et al. (n.d.) · Institutional Repositories DataBase (IRDB)
Chan, A. H. Y., Beyene, K. A., Lai, B., Kim, S., Wu, I., Al-Jawadi, R., Wu, M., Foot, H., Cheung, G., Walker, X. J., et al. (2026) · Rejuvenation Research · doi:10.1177/15491684261462413
Sheth, M. S., Jeong, I. J., Chu, A., Basque, S. R., Fang, J., McNaughton, C. D., Ko, D. T., Abdel-Qadir, H. M., Lee, D. S., & Udell, J. A. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2026.06.027
Alkhushaym, N., Almutairi, W., ALANAZI, S., Balharith, R., Alhifany, A. A., & Musa, I. R. (2026) · Research Square · doi:10.21203/rs.3.rs-10216709/v1
GSK3B variations influence renoprotective responses to dapagliflozin in diabetic kidney disease
Song, J., Xu, Y., Zhuang, Y., Yang, T., Chen, Y., Ying, C., Lu, Q., Wang, T., & Yin, X. (2026) · iScience · doi:10.1016/j.isci.2026.116862
“5 Moreover, cardiorenal impairment caused by diabetes mellitus is the major reason for increased treatment costs and decreased quality of life in T2DM, which demonstrates that the cardiorenal protective effect is the core indicator for evaluating hypoglycemic drugs.”
Ali, A., Maqsood, A., Mustafa, A., Hussain, Z., Ashraf, A., Sarfaraz, S., Butt, A., Shamoon, M., Ghafoor, L. A., Azam, H., et al. (2026) · Brain and Behavior · doi:10.1002/brb3.71616
Alharajin, R., AlTaweel, M., AlSubaiee, M., Almekhloof, S., Almusaad, A., Alarfaj, A. A., Alkhayyal, A. K., Altharman, N. M., Alalawi, A., Almannai, N., et al. (2026) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.041.02.6171
“18 GLP-1 RAs—such as liraglutide, dulaglutide, and semaglutide—enhance insulin secretion, suppress glucagon release, delay gastric emptying, and promote weight loss, with favorable cardiovascular effects shown in major outcome trials.”
Wang, Y., Kvedaravičienė, G., & Phan, P. (2026) · The Journal of Technology Transfer · doi:10.1007/s10961-026-10375-2
WILLOUGHBY, K. A., Nguyen, H. T., CHAPMAN, K. S. M., Peter, M. E., Aleppo, G., & Wolf, W. A. (2026) · The Science of Diabetes Self-Management and Care · doi:10.1177/26350106261475926
Hegaz, M. G., Aboud, M. Y. A., Kamel, A. I. I., Naveed, M. A., Elsayad, O. G., & Sorathia, A. Z. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02538-x
“…Association of Clinical Endo-crinologists (AACE) and ADA recommend a patient-centered approach while choosing the appropriate drug therapy, as cardiovascular, heart failure, and chronic kidney diseases come first before the risk of hypoglycemia, cost, effect on weight, and adverse events [4, 5].”
Cao, H. (2026) · International Conference on Biomedical and Intelligent Systems (IC-BIS) · doi:10.1145/3841905.3841961
“Its pathogenesis involves complex interactions among oxidative stress, inflammatory signaling, and metabolic pathways, making effective treatment challenging using conventional single-target strategies [2, 15].”
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-12-04
- Volume
- 44
- Issue
- Supplement_1
- Pages
- S111-S124
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4254445254
- Cited by
- 972
- References
- 94
- Citations by year
- 2026: 29 · 2025: 55 · 2024: 86 · 2023: 148 · 2022: 334 · 2021: 318 · 2020: 1
- FWCI
- 30.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- pharmacotherapy, diabetes management, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.